J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
J&J's pharmaceutical division is humming along, and the MedTech problems should be temporary.
Investing
J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
Fed-and-SEC desk, TradeNews USA (2026-10-13): J&J's 6% slide on an imperfect quarter is a gift to prospective buyers J&J's pharmaceutical division is humming along, and the MedTech problems should… Primary source: original at CNBC Finance (cnbc.com).
